Brief: China Biotech Services Sees Net Profit Attributable Of Not Less Than HK$200 Million For FY2022
28/02/2023 13:52
Feb 28 (Reuters) - China Biotech Services Holdings Ltd
8037.HK :
* SEES NET PROFIT ATTRIBUTABLE OF NOT LESS THAN HK$200
MILLION FOR
FY2022
* SEES INCREASE IN REVENUE OF GROUP'S SALE OF HEALTH-RELATED
AND
PHARMACEUTICAL PRODUCTS SEGMENT FOR FY2022
Further company coverage: 8037.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)